Loading clinical trials...
Loading clinical trials...
This protocol aims to evaluate the feasibility and benefit of Intrapulmonary Percussive Ventilation (IPV) to improve deposition of inhaled radiolabelled aerosols in fibrotic lung regions of patients with Idiopathic Pulmonary Fibrosis (IPF). Phase 1 of the protocol aims to identify the highest IPV pressure that is tolerated by individual patients. Secondary endpoints explore safety of IPV in IPF patients. Phase 2 of the protocol is a crossover randomized trial where patients will inhale 99mTc-labelled DiethyleneTriamine PentaAcetate (DTPA) aerosols with or without IPV. Aerosol deposition in HRCT-defined fibrotic regions of interest (ROI) is described by Single Photon Emission Computed Tomography (SPECT).
Age
50 - No limit years
Sex
ALL
Healthy Volunteers
No
Pulmonology Department, University Hospital, Tours
Tours, France
Start Date
November 23, 2022
Primary Completion Date
February 12, 2025
Completion Date
February 12, 2025
Last Updated
December 1, 2025
9
ACTUAL participants
intrapulmonary percussive ventilation
DEVICE
delivery of 99mTc-DTPA aerosol
RADIATION
Lead Sponsor
University Hospital, Tours
Collaborators
NCT06238622
NCT07299695
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions